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Appendiceal mucinous neoplasms have been the focus of considerable debate in recent years. We
histologically classified 70 appendiceal mucinous neoplasms into three categories: 32 mucinous adenoma,
23 mucinous neoplasm of uncertain malignant potential, and 15 mucinous adenocarcinomas. Immunohis-
tochemistry was performed for 24 proteins in different functional categories, specifically, oncogenic proteins
(bcl-2, b-catenin, CEA, C-erbB2, c-kit, Cox-2, Cyclin D1, EGFR, Ki-67, NF-jB, VEGF), tumor suppressors
(E-cadherin, FHIT, hMLH1, p53, p63, smad4), cell-cycle regulators (p21, p27, p16), and mucin proteins (MUC1,
MUC2, MUC5AC, MUC6). Our data showed that 9 out of the 24 proteins were more frequently altered in the
mucinous adenocarcinoma group than in the mucinous adenoma group (Po0.05), including b-catenin (13% in
mucinous adenoma vs 60% in mucinous adenocarcinoma), CyclinD1 (44 vs 87%), Ki-67 (high labeling index: 31
vs 67%), NF-jB (19 vs 60%), VEGF (16 vs 87%), E-cadherin (0 vs 47%), p53 (6 vs 40%), MUC2 (9 vs 67%), and
MUC5AC (3 vs 40%). The distinct immunoexpression profile of mucinous neoplasm of uncertain malignant
potential was placed between those of mucinous adenoma and mucinous adenocarcinoma (Po0.05). Moreover,
the mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous adenocarcinoma
categories displayed differences in terms of the number of altered markers among the nine proteins (Po0.05;
mean 1.4 vs 2.6 vs 5.5, respectively). In mucinous adenocarcinoma, the p53 status was related to disease-free
survival and overall survival of patients (Po0.05, both). NF-jB status and the number of altered protein markers
made statistically marginal impacts on disease-free survival; also b-catenin loss, on overall survival of patients.
In conclusion, protein immunoexpression profiles may facilitate the classification of appendiceal mucinous
neoplasms. In our study, the three tumor categories of mucinous adenoma, mucinous neoplasm of uncertain
malignant potential, and mucinous adenocarcinoma exhibited distinct immunoexpression profiles. Five and
more altered protein markers, p53 overexpression, NF-jB positivity, and b-catenin loss were predictive factors
of adverse clinical outcomes in appendiceal mucinous adenocarcinomas.
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Appendiceal mucinous neoplasms are rare tumors,
and their diagnostic classification is currently
controversial.1–12 Generally, in appendiceal tumors,
the appendiceal wall is totally fibrotic, thus each
layer in the wall cannot be discerned. Consequently,
it is difficult to establish the tumor invasion status.
In practice, the invasion front of appendiceal
mucinous adenocarcinomas tends to display a
broad pushing feature rather than an infiltrative
pattern, imitating its benign counterpart. In addi-
tion, even tumors with bland-looking (mucinous
adenoma-mimicking) cytoarchitecture can involve
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other organs, such as ovary and spleen, as well as
peritoneum (pseudomyxoma peritonei), and may
behave in an aggressive manner.
In 1995, appendiceal mucinous neoplasm of
uncertain malignant potential was introduced as a
diagnostic entity.2 Mucinous neoplasm of uncertain
malignant potential was defined in detail, not to use
mucinous neoplasm of uncertain malignant poten-
tial as the diagnostic term excessively. In 2005, the
term ‘mucinous neoplasm of uncertain malignant
potential’ was revisited by Pai et al4 Under condi-
tions where the muscularis mucosae was lost and
invasion was unclear, appendiceal mucinous neo-
plasm displaying bland cytoarchitecture, but fea-
tures of (1) epithelium pushing deeply into
underlying tissue, (2) cystic gland-like structure in
wall, or (3) uncertainty of complete excision, such as
positive proximal margin or extensive mucin on the
appendiceal serosa, were classified as mucinous
neoplasm of uncertain malignant potential.4 How-
ever, the issue of whether mucinous neoplasm of
uncertain malignant potential progresses toward
mucinous adenoma or mucinous adenocarcinoma
in terms of biologic behavior remains to be estab-
lished. A number of distinguished researchers have
classified appendiceal mucinous neoplasm into two
categories, specifically, low-grade appendiceal mu-
cinous neoplasm or mucinous adenocarcinoma.3
Molecular changes, such as protein alterations,
which may correspond with the biologic behavior of
tumors, are helpful in classifying tumors and
predicting clinical outcome. Following examination
of the existing literature for immunoexpression data
on proteins in mucinous neoplasms of various
organs, including colorectum,13–18 pancreas,19,20
ovary,21–23 and appendix,24–26 we focused on 24
proteins. The immunoexpression profiles of differ-
ent functional proteins in three groups—mucinous
adenoma, mucinous neoplasm of uncertain malig-
nant potential, and mucinous adenocarcinoma of
the appendix—were analyzed. Additionally, the




We retrieved database information on appendiceal
mucinous neoplasms, which were resected at three
affiliated hospitals to Seoul National University
College of Medicine. In total, 70 cases were included
in the study, of which 28 were resected at Seoul
National University Hospital from 2003 to 2007, 25
at Seoul National University Boramae Hospital from
1998 to 2007, and 17 at Bundang Seoul National
University Hospital from 2003 to 2007. Clinical
information, including age, sex, survival data,
metastasis to distant organs, recurrence, poor re-
sponse to treatment or tumor-associated death, was
obtained from medical records. The follow-up
period was 12–60 months in malignant cases, and
7–120 months in the remaining cases. The histology
of all cases was reviewed by two pathologists (MSC
and SOY).
Tissue Array
Two to five different representative areas per case
were selected. Each tissue core (2.0 mm in diameter)
was punched out from the original paraffin block of
tumor samples using a trephine apparatus. The
punched cores were arranged in a new tissue array
paraffin block, containing 59 tissue cores and 1 ink
core as a direction indicator. Five tissue array blocks
(300 cores) were newly manufactured, which in-
cluded 70 cases of appendiceal mucinous neo-
plasms and 32 nonneoplastic appendiceal tissues
as a control.
Immunohistochemistry
Immunohistochemistry was performed on 4mm
thick paraffin-embedded tissue sections using the
streptavidin–biotin peroxidase complex method
after microwave or autoclave-based antigen retrie-
val. We selected 24 antibodies for immunostaining
(Table 1), specific for oncogenic proteins (bcl-2,
b-catenin, CEA, C-erbB2, c-kit, Cox-2, Cyclin D1,
EGFR, Ki-67, NF-kB, VEGF), tumor suppressors
(E-cadherin, FHIT, hMLH1, p53, p63, smad4),
cell-cycle regulators (p21, p27, p16), and mucins
(MUC1, MUC2, MUC5AC, MUC6). Immunohisto-
chemistry was performed for the 24 proteins after
a test procedure using human control slides
for immunostaining (Superbiochips Laboratories,
Seoul, Korea).
Data from immunohistochemical staining are
presented in Table 2. In cases where more than
10% of tumor cells are immunoreactive, immunos-
taining is regarded as positive27,28 or high labeling
index for Ki-67.29 MUC1, MUC2, MUC5AC, and
MUC6 protein expression status is positive when
more than 20% of the tumor cells display immu-
noexpression in the cytoplasm.27 The immunoex-
pression profiles of protein markers were evaluated
in each case. In cases displaying dissimilarities
between appendix and extra-appendiceal organ
lesions, changes in protein marker patterns within
any individual organs were regarded as alterations
in the case.
Statistical Analysis
Pearson’s w2 and Fisher’s exact tests were used to
examine differences between the variables. Overall
survival was measured from the date of diagnosis to
death or last follow-up visit. Disease-free survival
was calculated from the date of surgical resection to
initial evidence of treatment failure. Patient survival
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rates were obtained using the Kaplan–Meier meth-
od, and differences in survival compared using the
log-rank test. Multivariate analysis was performed
using the Cox proportional hazards model. P-values
of o0.05 were considered statistically significant.
All statistical analyses were carried out using SPSS/
PC version 12.0 for Windows (SPSS Inc., Chicago,
IL, USA).
Table 2 Clinical information on 70 patients with appendiceal mucinous neoplasms and per tumor category








Age at diagnosis (years)
Mean 64.2 63.1 64.8 64.7
Range 10–98 10–86 45–98 45–87
Sex
Male 32 15 14 3
Female 38 17 9 12
Clinical outcome
Dead of disease 4 0 0 4
Alive without disease 63 32 23 8
Alive with disease 3 0 0 3
Table 1 Antibodies used for immunohistochemical analyses





bcl-2 Microwave 1:100 DAKO Negative Nucleus
b-Catenin Microwave 1:200 Transduction Membrane Lossa
CEA Microwave 1:50 DAKO Negative Cytoplasm
c-erbB2 Microwave 1:75 DAKO Negative Membrane
c-kit Microwave 1:250 DAKO Negative Cytoplasm
Cox-2 Microwave 1:400 Cayman Negative Cytoplasm
Cyclin D1 Microwave 1:300 DAKO Nucleusb Nucleus
EGFR Autoclave 1:200 DAKO Negative Cytoplasm
Ki-67 Microwave 1:100 DAKO Nucleusb Nucleus
NF-kB Autoclave 1:100 Santa Cruz Negative Nucleus
VEGF Microwave 1:250 Santa Cruz Negative Cytoplasm
Tumor suppressor proteins
E-cadherin Microwave 1:200 Transduction Membrane Loss
FHIT Microwave 1:250 Zymed Nucleus Loss
hMLH1 Microwave 1:50 Oncogene Nucleus Loss
p53 Microwave 1:100 DAKO Negative Nucleus
p63 Microwave 1:100 Santa Cruz Negative Nucleus
smad4 Microwave 1:50 Santa Cruz Nucleus Loss
Cell-cycle regulators
p21 Microwave 1:100 Santa Cruz Nucleus Loss
p27 Microwave 1:100 Santa Cruz Nucleus Loss
p16 Autoclave 1:50 Pharmingen Nucleus Loss
Mucin proteins
MUC1 Microwave 1:100 Novocastra Negative Cytoplasm
MUC2 Microwave 1:100 Novocastra Cytoplasmc Cytoplasm
MUC5AC Microwave 1:100 Novocastra Negative Cytoplasm
MUC6 Microwave 1:100 Novocastra Negative Cytoplasm
a
Negative immunostaining for b-catenin in the cytoplasmic membrane of tumor cells was an important finding, although nuclear accumulation
is a well-known alteration.
b
Nuclear staining in the base of the normal crypt was observed.
c
MUC2 was positive in the base of the normal crypt. MUC2 was strongly and diffusely positive in the whole cytoplasm of tumor cells.
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Results
Classification of Appendiceal Mucinous Neoplasms
The clinicopathological features of 70 appendiceal
mucinous neoplasm cases are listed in Table 2.
The 70 resected tumors were categorized using a
three-tiered system, specifically, 32 mucinous ade-
nomas, 23 mucinous neoplasms of uncertain malig-
nant potential, and 15 mucinous adenocarcinomas
(Table 2). In terms of mucinous neoplasm of
uncertain malignant potential, we followed the
definition of Pai et al4 (Figure 1). We adopted the
Figure 1 Histologic features of appendiceal mucinous neoplasms. (a) Mucinous adenoma. (b) Mucinous neoplasm of uncertain
malignant potential. (c–e) Mucinous adenocarcinoma with low-grade atypia showing scarce epithelium in the appendix (c), involving
ovary (d), and peritoneum (e).
Appendiceal mucinous neoplasm
SO Yoon et al
1105
Modern Pathology (2009) 22, 1102–1112
mucinous adenocarcinoma definition of Carr et al2,9
which included tumors displaying destructive in-
vasion of the appendiceal wall, architectural
complexity, cytologically high-grade atypia, or
plump amount of epithelium outside the appendix
(Figures 1 and 2). Interestingly, the proportions of
tumor categories were strikingly different between
tertiary-care and secondary-care hospitals. In the
tertiary-care hospital (Seoul National University
Hospital), 24, 42, and 34% mucinous adenoma,
mucinous neoplasm of uncertain malignant poten-
tial, and mucinous adenocarcinoma cases were
Figure 2 (a–c) Mucinous adenocarcinoma showing a broad invasion front in appendix (a, b) and involving peritoneum (c). (d–f)
Mucinous adenocarcinoma with high-grade atypia in appendix (d, e) and involving peritoneum (f).
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reported, respectively. Meanwhile, in two second-
ary-care hospitals, the proportions of mucinous
adenoma, mucinous neoplasm of uncertain malig-
nant potential, and mucinous adenocarcinoma were
76, 16, and 8% (Seoul National University Boramae
Hospital) and 82, 12, and 6% (Bundang Seoul
National University Hospital), respectively.
Differential Immunoexpression Profiles of Proteins in
Mucinous Adenoma, Mucinous Neoplasm of
Uncertain Malignant Potential and Mucinous
Adenocarcinoma
Among the 24 protein markers, 9 were more
frequently altered in mucinous adenocarcinoma,
compared to the mucinous adenoma group
(Figure 3). Immunoexpression profiles of nine
proteins (b-catenin, Cyclin Di, Ki-67, NF-kB, VEGF,
E-cadherin, p53, MUC2, and MUC 5AC) according
to tumor category are presented in Figure 4 and
Table 3.
The alteration frequencies of b-catenin, CyclinD1,
Ki-67, E-cadherin, MUC2, and MUC5AC in muci-
nous neoplasm of uncertain malignant potential
approached those in mucinous adenoma, whereas
frequencies of NF-kB, VEGF and p53 were compar-
able to those in mucinous adenocarcinoma.
Discriminative Numbers of Altered Protein Markers in
Mucinous Adenoma, Mucinous Neoplasms of
Uncertain Malignant Potential, and Mucinous
Adenocarcinoma Groups
The number of altered protein markers per case was
determined. Mean numbers were significantly dif-
ferent among the three groups. Mucinous neoplasm
of uncertain malignant potential was placed in the
middle spectrum between mucinous adenoma and
mucinous adenocarcinoma, with respect to the
mean number of altered protein markers, estimated
as 1.4 (median 1.0, range 0–5) in mucinous adeno-
ma, 2.6 (median 2.0, range 0–6) in mucinous
neoplasms of uncertain malignant potential, and
5.5 (median 5.0, range 3–8) in mucinous adenocar-
cinoma (Po0.05; Figure 5).
There were several cases, which unexpectedly
showed marker alteration (Figure 5; Supplementary
Information-1). A mucinous adenoma case (No. 27)
displayed alterations in five markers. In this case,
small mucinous adenoma (0.8 cm in tumor size) in
appendix was observed incidentally, in the speci-
men undergone right hemicolectomy due to syn-
chronous adenocarcinomas of the tubular type in
ascending colon and cecum. In the mucinous
neoplasm of uncertain malignant potential group,
cases 34 and 38 displayed five altered marker
proteins, and six altered markers were detected in
case 44. Additionally, cases 37, 45, and 52 showed
one altered marker, whereas case 47 presented no
marker alterations. However, these cases displayed
no specific features that could allow differentiation
from other mucinous neoplasms of uncertain malig-
nant potential patients, except that case 37 dis-
played mucinous adenoma-mimicking microscopic
features, but a positive proximal resection margin.
Immunoexpression Status in the Appendix and Extra-
appendiceal Organ in Mucinous Adenocarcinoma
In this study, extra-apendiceal organ involvement
was pathologically confirmed in 14 out of 15
mucinous adenocarcinoma cases as follows: 8 cases
in peritoneum, 8 in ovary, 7 in omentum, 3 in other
intestinal segments, 3 in uterus, 2 in salpinx, 2 in
spleen capsule, and 2 in regional lymph nodes.
In 10 cases, alterations in protein markers in the
appendix and extra-appendiceal organ were slightly
dissimilar. Moreover, the immunoexpression status
within the mucinous adenocarcinoma group was
not related to cytologic atypia, architecture com-
plexity, or extent of extra-appendiceal organ invol-
vement. For instance, case 68 displayed mucinous
neoplasm of uncertain malignant potential-mimick-
ing cytoarchitecture in the appendix per se, and
more complex architecture in the ovary. However,
this patient presented six altered markers in the
appendix and four in the ovary. In two mucinous
adenocarcinoma cases with high cytologic atypia,
one displayed five and six altered markers in the
appendix and extra-appendiceal lesion, whereas
five altered markers each in the appendix
and extra-appendiceal lesion were observed in the
other case.
Clinical Significance of Immunoexpression Patterns in
Mucinous Adenocarcinoma
In the mucinous adenocarcinoma group, the number
of altered protein markers had an impact on clinical
response. The mean number of altered protein
markers in the mucinous adenocarcinoma group
was 5.5, and median number, 5. The median number
was rated as a cutoff, and clinical significance of the
number of altered protein markers was evaluated.
Eleven mucinous adenocarcinoma cases displayed
alteration of five and more proteins. Treatment
failure was reported for seven (64%) of these cases.
Treatment failure was defined as metastasis to
distant organs, recurrence, poor response to treat-
ment or tumor-associated death after initial treat-
ment at any time during the follow-up period.
Meanwhile, four cases displayed alteration of four
and less proteins, none of whom exhibited treatment
failure. In univariate analysis, 11 cases with five and
more protein alteration demonstrated a shorter
period of disease-free survival than the 4 cases with
four and less protein alteration, although the
statistical significance was marginal (P¼ 0.087;
Figure 6a).
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Figure 3 Representative immunohistochemical features of nine protein markers, which are more frequently altered in mucinous
adenocarcinoma than mucinous adenoma (Po0.05). (a) Cyclin D1, nuclear positive. (b) Ki-67 (high labeling of nuclear positive). (c) NF-
kB, nuclear positive. (d) VEGF, cytoplasmic positive. (e) E-cadherin, cytoplasmic membranous loss. (f) p53 overexpression (nuclear
accumulation). (g) MUC2, cytoplasmic positive. (h) MUC5AC, cytoplasmic positive.
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In terms of clinical implications of individual
markers, p53 alterations were associated with treat-
ment failure in mucinous adenocarcinoma
(P¼ 0.041). Of the 15 mucinous adenocarcinoma
cases, 6 displayed p53 overexpression, and treat-
ment failure was reported for 5 (83%) of these cases.
Meanwhile, only two (22%) of the nine p53-negative
mucinous adenocarcinoma cases resulted in treat-
ment failure. In univariate analysis, p53-overexpres-
sing mucinous adenocarcinoma cases (n¼ 6)
showed a shorter period of disease-free survival
than p53-negative cases (n¼ 9; P¼ 0.011; Figure 6b).
In addition, NF-kB-positive mucinous adenocarci-
noma cases (n¼ 9) displayed a shorter period of
disease-free survival than NF-kB- negative cases
(n¼ 6; P¼ 0.083; Figure 6c). Regarding overall
survival of patients, p53 overexpression was related
to lower rate of overall survival (P¼ 0.040), and b-
catenin loss tended to show lower rate of overall
survival (P¼ 0.080; Figures 7a and b). Multivariate
analysis disclosed no independent prognostic fac-
tors among protein markers.
Treatment failure was not reported for any of the
mucinous adenoma and mucinous neoplasm of
uncertain malignant potential cases during the
follow-up period.
Discussion
We suggest that immunoexpression profiles of the
nine protein markers are representative for appen-
diceal mucinous adenocarcinoma. Although appen-
diceal mucinous neoplasm accompanying
peritoneal lesions are cytoarchitecturally benign in
appearance, the molecular status of the tumor is
consistent with features of mucinous adenocarcino-
ma, which are significantly different from those of
Figure 4 Differential immunoexpression patterns of proteins in appendiceal mucinous neoplasms according to tumor category.
Immunoexpression of nine protein markers in mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous
adenocarcinoma groups, reveals significant differences (Po0.05). BENIGN, mucinous adenoma; UMP, mucinous neoplasm of uncertain
malignant potential; MALIGNANT, mucinous adenocarcinoma.
Table 3 Altered immunoexpression of proteins per tumor category
Mucinous adenoma
(n¼ 32); percent (no.)
Uncertain malignant potential
(n¼ 23); percent (no.)
Mucinous adenocarcinoma
(n¼15); percent (no.)
b-Catenin, loss 13 (4) 9 (2) 60 (9)
CyclinD1, positive 44 (14) 44 (10) 87 (13)
Ki-67, high index 31 (10) 35 (8) 67 (10)
NF-kB, positive 19 (6) 52 (12) 60 (9)
VEGF, positive 16 (5) 83 (19) 87 (13)
E-cadherin, loss 0 4 (1) 47 (7)
p53, overexpression 6 (2) 39 (8) 40 (6)
MUC2, positive 9 (3) 0 67 (10)
MUC5AC, positive 3 (1) 0 40 (6)
Appendiceal mucinous neoplasm
SO Yoon et al
1109
Modern Pathology (2009) 22, 1102–1112
mucinous adenoma or mucinous neoplasms of
uncertain malignant potential. Meanwhile, once
cases are classified as mucinous adenocarcinoma,
the number of altered markers or individual marker
alterations are not related to the cytoarchitecture
grade of appendiceal and extra-appendiceal lesions,
or extent of extra-appendiceal involvement. To date,
few molecular studies on appendiceal mucinous
neoplasms and even more limited immunohisto-
chemistry analyses have been performed. To the best
of our knowledge, limited information is available
on mucin, E-cadherin, and p53 immunoexpression
patterns focusing on both benign and malignant
tumors.26
We propose that the number of altered protein
markers, p53 status, NF-kB status, and b-catenin
status are of clinical significance in appendiceal
mucinous adenocarcinomas. In other words,
p53 overexpression may signify shorter periods of
disease-free survival and overall survival of pa-
tients. In addition, five and more altered markers
and NF-kB positivity or b-catenin loss may be a sign
of shorter periods of disease-free survival or overall
survival, respectively.
In this study, a three-tiered classification of
appendiceal mucinous neoplasms is supported by
an analysis based on altered protein markers and
Figure 6 Disease-free survival plots in mucinous adenocarcinoma patients according to (a) number of altered protein markers; five and
more altered markers (solid line) vs four and less altered markers (dotted line; P¼ 0.087); (b) p53 status; overexpression (solid line) vs
negative (dotted line; P¼ 0.011); and (c) NF-kB status; nuclear positive (solid line) vs negative (dotted line; P¼0.083).
Figure 7 Overall survival plots in mucinous adenocarcinoma patients, according to (a) p53-status; overexpression (solid line) vs negative
(dotted line; P¼ 0.004) and (b) b-catenin status; loss (solid line) vs preservation (dotted line; P¼ 0.080).
Figure 5 Number of altered protein markers among nine proteins
in appendiceal mucinous neoplasms. Mean numbers of altered
markers in mucinous adenoma, mucinous neoplasm of uncertain
malignant potential and mucinous adenocarcinoma groups were
1.4, 2.6, and 5.5, respectively (Po0.05). BENIGN, mucinous
adenoma; UMP, mucinous neoplasm of uncertain malignant
potential; MALIGNANT, mucinous adenocarcinoma.
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clinical outcome. We adopted the three-tiered system
suggested by Carr et al,2 and applied the strict
guidelines of Carr et al2 and Pai et al4 to define
mucinous neoplasms of uncertain malignant poten-
tial. In fact, Pai et al4 suggested a four-tiered system,
specifically, mucinous adenoma, mucinous neo-
plasm of uncertain malignant potential, low malig-
nant potential, and mucinous adenocarcinoma. Pai et
al4 proposed the term low malignant potential for
tumors that were cytoarchitecturally similar to
mucinous adenoma, but neoplastic cells penetrated
appendiceal wall and were present in peritoneal
implants, and there was no metastasis. Taking into
account this four-tiered system, 6 out of 15 mucinous
adenocarcinoma cases in our study may be defined as
low malignant potential. However, we cannot cate-
gorically discriminate between six cases of so-called
low malignant potential and nine cases of higher
grade atypia-mucinous adenocarcinoma, in terms of
altered protein markers and clinical outcome
(Supplementary Information-1 and -2). The above-
described six cases may belong to low-grade muci-
nous neoplasm in two-tiered categorization system
(low-grade mucinous neoplasm and mucinous ade-
nocarcinoma) suggested by Misdraji et al.3 Like the
preceding, so-called low-grade mucinous neoplasm
and higher grade atypia-mucinous adenocarcinoma
were not separated, based on altered protein markers
and clinical outcome (Supplementary Information-1
and -2). The tumors of low-grade cytologic atypia
(nucleomegaly, nuclear stratification, rare mitotic
figures, single cell necrosis) and minimal architectur-
al complexity (viliform, flat epithelial proliferation,
small papillary excrescence) was designated as
low-grade mucinous neoplasm by Misdraji et al,3
thus the concept of low-grade mucinous neoplasm
encompasses mucinous adenoma through to low-
grade atypia-mucinous adenocarcinoma. In daily
practice, the term ‘low-grade mucinous neoplasm’
may be employed in ambiguous cases. However,
we preferred a three-tiered categorization, along
with a descriptive explanation, for instance,
mucinous adenocarcinoma with high-grade or
low-grade atypia.
In this study, 21 patients classified as mucinous
neoplasm of uncertain malignant potential appeared
close to mucinous adenoma, because no adverse
clinical events were observed such as recurrence,
metastasis, or high-grade transformation after initial
treatment. In the series of Carr et al,2 2 out of 18
patients with mucinous neoplasm of uncertain
malignant potential displayed evidence of recur-
rence, one at 6 months of follow-up and the other at
52 months after appendectomy. However, the first
patient had a coexisting ‘ovarian mucinous tumor
with low malignant potential’, which may have been
an appendiceal mucinous adenocarcinoma invol-
ving ovary rather than a double organ primary
tumor. In the study by Pai et al,4 late recurrences
occurred in several patients with mucinous neo-
plasm of uncertain malignant potential during long-
term follow-up. A small percentage of mucinous
neoplasm of uncertain malignant potential tumors
can develop into late recurrence. In our analysis,
mucinous neoplasm of uncertain malignant poten-
tial cases exhibited differential protein immunoex-
pression profiles, which were distinguishable from
those of benign and malignant appendiceal muci-
nous neoplasms. Hence, mucinous neoplasm of
uncertain malignant potential is justified as a
separate diagnostic entity in terms of clinical
behavior and molecular changes.
Extra-appendiceal involvement (including pseu-
domyxoma peritonei) was additionally noted in 14
(18%) out of 70 patients, but only 3 (7%) out of 42
patients from secondary-care hospitals among our
data. According to a 10-year nationwide study from
the Netherlands, 9% of patients with appendiceal
lesions developed pseudomyxoma peritonei.30 The
proportion according to tumor category in a tertiary-
care hospital was comparable to that in an AFIP
series by Carr et al,2 ie. mucinous adenoma/
mucinous neoplasm of uncertain malignant poten-
tial/mucinous adenocarcinoma was 24/42/34% in
our data, and 28/17/55% in AFIP series.
In conclusion, immunoexpression profiling may
be an effective complementary strategy in the
classification of appendiceal mucinous neoplasms.
Appendiceal mucinous adenoma, mucinous neo-
plasm of uncertain malignant potential, and muci-
nous adenocarcinoma are distinct in terms of
protein marker alterations. In appendiceal muci-
nous adenocarcinoma cases, five and more altered
protein markers, p53 overexpression, NF-kB positi-
visty, and b-catenin loss are factors associated with
unfavorable clinical events, such as treatment fail-
ure, shorter period of disease-free survival, and
shorter period of overall survival.
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